Free Trial

Medpace Q2 2024 Earnings Report

Medpace logo
$337.28 +2.13 (+0.64%)
(As of 12/20/2024 05:16 PM ET)

Medpace EPS Results

Actual EPS
$2.75
Consensus EPS
$2.54
Beat/Miss
Beat by +$0.21
One Year Ago EPS
$1.93

Medpace Revenue Results

Actual Revenue
$528.10 million
Expected Revenue
$528.41 million
Beat/Miss
Missed by -$310.00 thousand
YoY Revenue Growth
+14.60%

Medpace Announcement Details

Quarter
Q2 2024
Time
After Market Closes

Conference Call Resources

First JFK… next Elon? (Ad)

Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medpace? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medpace and other key companies, straight to your email.

About Medpace

Medpace (NASDAQ:MEDP) engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

View Medpace Profile

More Earnings Resources from MarketBeat

Upcoming Earnings